Corbus doses first patient in Phase 2 study of Resunab for cystic fibrosis treatment
Resunab is a novel oral drug designed to target the resolution of chronic inflammation and debilitating fibrosis associated with disease progression in CF across all cystic fibrosis transmembrane
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.